论文部分内容阅读
最近一项前瞻性研究发现雌激素拮抗剂他莫昔芬治疗未切除的肝细胞癌(HCC),可使其生存期延长,特别是对女性病人。本研究对白种人HCC的雌激素受体水平及其对肝癌切除后结果的影响进行研究。 材料和方法:选取1992年至1993年33例手术前后未行化疗、放疗或肝动脉栓塞治疗的病人作为研究对象。31例取自切除的肝癌组织、2例来自剖腹探查活检,术后随访1至43个月。以单克隆抗体固相酶联免疫法检测雌激素受体(ER)和孕激素受体(PgR)。 结果:33例中伴有乙型肝炎者3例,丙型
A recent prospective study found that the estrogen antagonist tamoxifen treatment of unresected hepatocellular carcinoma (HCC) can extend its survival, especially in female patients. This study investigated the level of estrogen receptors in Caucasian HCC and its effect on the outcome of HCC resection. Materials and Methods: Thirty-three patients who underwent chemotherapy, radiotherapy, or hepatic artery embolization before and after surgery from 1992 to 1993 were selected as the study subjects. Thirty-one patients were enrolled from the resection of hepatocellular carcinoma and 2 patients were examined by laparotomy. Biopsy was followed up for 1 to 43 months. The estrogen receptor (ER) and progesterone receptor (PgR) were detected by monoclonal antibody solid-phase enzyme-linked immunosorbent assay. Results: 33 cases were associated with hepatitis B in 3 cases, type C